Zymeworks (ZYME) EBITDA Margin (2021 - 2026)
Zymeworks (ZYME) posted EBITDA Margin of 1956.73% for Q1 2026, down 11.46% sequentially from 1755.55% in Q4 2025, and down 186225.0% YoY from N/an in Q1 2025.
Zymeworks (ZYME) EBITDA Margin (2021 - 2026) Analysis & Trends
Zymeworks has reported EBITDA Margin for 6 years, with the latest figure at 1956.73% in Q1 2026.
- Quarterly EBITDA Margin fell 186225.0% year-over-year to 1956.73% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 140.35% (down 658.0% YoY) and the FY2025 annual result came in at 87.34%, up 9235.0% from the prior year.
- EBITDA Margin slipped to 1956.73% in Q1 2026 per ZYME's latest filing, from 1755.55% in the prior quarter.
- Over five years, EBITDA Margin peaked at 98.28% in Q4 2022 and troughed at 3793.63% in Q1 2022.
- A 5-year average of 751.85% and a median of 213.78% in 2024 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2023 and 2026: EBITDA Margin soared 371695 bps in 2023, then tumbled 186225 bps in 2026.
- Over 5 years, EBITDA Margin stood at 98.28% in 2022, then sank by 241 bps to 138.37% in 2023, then surged by 48 bps to 71.6% in 2024, then tumbled by 2352 bps to 1755.55% in 2025, then decreased by 11 bps to 1956.73% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 1956.73%, 1755.55%, and 80.07% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Zymeworks | 1.79 Bn | 1.52 Bn | - | -918.95% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -918.95% |
| Mar 31, 2026 | -1,956.73% |
| Dec 31, 2025 | -1,755.55% |
| Sep 30, 2025 | -80.07% |
| Jun 30, 2025 | -1.38% |
| Mar 31, 2025 | -94.48% |
| Dec 31, 2024 | -71.60% |
| Sep 30, 2024 | -213.78% |
| Jun 30, 2024 | -222.87% |
| Mar 31, 2024 | -376.89% |
| Dec 31, 2023 | -138.37% |
| Sep 30, 2023 | -201.36% |
| Jun 30, 2023 | -772.84% |
| Mar 31, 2023 | -76.68% |
| Dec 31, 2022 | 98.28% |
| Sep 30, 2022 | -1,914.03% |
| Jun 30, 2022 | -1,209.54% |
| Mar 31, 2022 | -3,793.63% |
| Dec 31, 2021 | -510.61% |
| Sep 30, 2021 | -1,387.12% |